Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. - Wikidata - awgldk - TriplyDB

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

http://www.wikidata.org/entity/Q37292366

about

Estimating the Effect of Health Insurance on Personal Prescription Drug Importation A blueprint for pharmacy benefit managers to increase value Costs and benefits of free medications after myocardial infarction.Medicare Part D--lessons learned and guidance for health-care reform.Drug company-sponsored patient assistance programs: a viable safety net?Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.The economics of medicines optimization: policy developments, remaining challenges and research priorities.Benefits of statin therapy and compliance in high risk cardiovascular patients.Estimated cost of universal public coverage of prescription drugs in Canada Racial/ethnic disparities in access to physician care and medications among US stroke survivors Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis.Treatment differences by health insurance among outpatients with coronary artery disease: insights from the national cardiovascular data registry.Medication adherence and readmission after myocardial infarction in the Medicare population Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis The effects of payments for pharmaceuticals: a systematic literature review.Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator Assessing the impact of drug use on hospital costs.Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies Impact of Physician-Coordinated Intensive Follow-Up on Long-Term Medical Costs in Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention.Underprescription of beneficial medicines in older people: causes, consequences and prevention.Impediments to adherence to post myocardial infarction medications.Patient co-payment and adherence to statins: a review and case studies.Cost-effectiveness of adherence-enhancing interventions: a systematic review.The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.Action and coping plans related to the behavior of adherence to drug therapy among coronary heart disease outpatients.Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.The association between adherence to cardiovascular medications and healthcare utilization.Incorporating social network effects into cost-effectiveness analysis: a methodological contribution with application to obesity prevention.Purchasing prescription drugs in Canada: hang together or hang separately.Medication adherence after myocardial infarction: a long way left to go.Physicians' attitudes toward post-MI aspirin prophylaxis: findings from an online questionnaire in Europe and Latin America.Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.Non-adherence to cardiovascular medications.β-blocker therapy after acute myocardial infarction.Predictors of adherence to treatment by patients with coronary heart disease after percutaneous coronary intervention.Discharge counseling for patients with heart failure or myocardial infarction: a best practices model developed by members of the American College of Clinical Pharmacy's Cardiology Practice and Research Network based on the Hospital to Home (H2H) In

P2860

Q28272855-B6952F7B-5E4D-43CB-A4F1-575CC85F1E32 Q28766235-DA11684B-A6B0-47F1-AEB7-EC659A86E8CE Q33585275-7148E726-C5E2-4821-98EB-A0C11FB01993 Q33611440-A94F416E-36DE-466A-AC39-B0B10EA6348B Q33864928-FCAC0C62-76A5-4A44-B839-F9D0820D4743 Q34055633-A2604FEF-5653-4D4A-A346-8A613DC8BCC6 Q34132415-BBCDFD41-CBEE-4A38-B0DB-5D193920C868 Q34187551-DF8FD007-4BB1-4071-ACE5-7171706F4F57 Q34467493-F4969CAD-D3B8-49A3-A2BA-A07BDE0F7375 Q34536283-15C17537-9972-4B01-9E57-2BE7B29569DC Q34556420-89B974AE-4781-48CE-8608-16F9799EEAA8 Q34572760-60B13410-D9DA-435A-9BA8-FC648CBDED09 Q35063975-0825BA63-368C-486D-9CFC-4A9535BA96AD Q35675611-55D827BE-14C7-4E31-8C32-457387255590 Q36062323-0FAC5F23-6DEA-4CA7-BF33-3713A5822569 Q36323515-38339663-8317-4561-9426-F3448058466C Q36469832-A31517BA-B959-4CCB-A3AF-E0028721C3F5 Q36949147-35B2EDDA-05E4-4F3C-A4BA-082C4E607623 Q37159754-347F87BE-EBB1-49D6-91D4-39D962B1218C Q37187904-A4BD4647-EB8B-4157-A74A-D9C7045C46E0 Q37196480-7D37C633-23FF-40ED-9CF7-863529AD87C0 Q37229332-F6359805-A84C-4051-A60C-732A8DD932BE Q37719015-0427D99B-D7C6-4B31-932C-D94E2B92DF03 Q38014125-6290ECB7-A40C-4D3C-911B-98FA26B701ED Q38068349-8B7EBB3E-9BF9-458A-BDE7-A2AF3530FE23 Q38154826-133E7ECA-8362-483E-9535-725233DB08CA Q38687403-9923307F-0CD9-4022-B9CE-10C318451258 Q38823423-B2EE544D-70C3-4CCC-AD0F-1A2F56189A7C Q39237737-37EF553C-B9B2-43DA-A834-F5580C2F0438 Q40366831-ACE268B2-A1D2-4527-8AC1-7078DF402B29 Q40832804-365AFC94-D65E-459C-85A7-B6515EBE3E16 Q41829840-8FBF9D04-A702-42E0-B419-C768052B5BEE Q42745017-17200AB9-1C5C-42E0-A38E-CE5CF3D55A35 Q43198230-CE14098B-8A06-4758-AB95-4C524DBACC37 Q43235282-F93F51B7-8022-453C-A498-C83609F898BA Q43935033-1607CE3F-1704-4AB4-8199-B52DF3CE2BA5 Q45230929-CFA2933C-5CD0-4F4B-8E24-D7C62D7F30DE Q46894869-72BCD248-5FCF-46C7-BD31-2DBE6BE4B83C Q47309703-211524E6-6090-40B2-8B1C-B0FD6FA03A74 Q50863884-282AC19E-8F06-460B-9C43-D126DF1EBD47

P2860

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

http://www.wikidata.org/entity/Q37292366

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@en

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@nl

type

label

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@en

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@nl

prefLabel

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@en

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@nl

P1433

Q37292366-9237AB2A-C56C-4D83-9F67-07D09F820C52

P1476

Q37292366-925CF480-05AA-4071-872D-98E2A9F95144

P2093

Q37292366-5056657E-042E-402D-B19E-C35CCED9C0F4

Q37292366-E3DA7719-8A76-4CD9-B9DE-80ECB55A62C9

Q37292366-F571F70D-B373-44E4-B9D7-4F72C74D93DE

Q37292366-FA6D4920-56B4-4734-BBA1-FC30E024AE20

P2860

Q37292366-0E4CE333-B86A-49D7-82AB-478BA799F825

Q37292366-0F0AE19A-7E22-42BE-94B2-6170A4BE39C3

Q37292366-179435BA-B7BD-46A2-BE02-A767383CFB05

Q37292366-1E171D6A-F3A2-494D-8503-D5F118C61DC4

Q37292366-23D39178-328F-4694-9102-759D8B92C3C1

Q37292366-2E280474-B042-42B0-A6AA-3BE1225AE5BD

Q37292366-320AB683-4324-41CF-93F7-E547A53A519B

Q37292366-32DC59C1-E20C-4F87-9A89-2021B11AE0D0

Q37292366-392A204A-7CEB-4DC8-98C2-81DD009FD14D

Q37292366-3EA25DF4-A323-478A-A615-240588414B0E

P304

Q37292366-BC6B6099-9326-4843-9118-92629AA79821

P31

Q37292366-6D2AC57B-7A4C-4090-86B8-DFC53FDE7AEA

P356

Q37292366-CF64038B-5126-45B5-B0DC-F4F89D010182

P407

Q37292366-C77C7538-D9C1-4C2C-BB38-371C1970B998

P433

Q37292366-9A440E3D-C1C1-43E3-926C-99D0F23E6BAE

P478

Q37292366-8F1CB14A-8B95-421A-A15F-A2638ABEB246

P50

Q37292366-21A30F50-D3A0-44D0-9F08-897AB9B9973C

P577

Q37292366-C0668F8B-63C8-4A9D-B995-DF0EE1809D1A

P698

Q37292366-ECD7ECB9-FA4E-48BB-8880-3BC5CE6D9967

P921

Q37292366-F712246C-1435-4D72-8A9B-61A8A3334B75

P932

Q37292366-1FD4C6A9-692A-4BFD-96CB-7064BBE2A04C

P356

CIRCULATIONAHA.107.735605

P1433

P1476

Cost-effectiveness of providin ...... rction Medicare beneficiaries.

@en

P2093

Amanda R Patrick

http://www.w3.org/2001/XMLSchema#string

Jerry Avorn

http://www.w3.org/2001/XMLSchema#string

Niteesh K Choudhry

http://www.w3.org/2001/XMLSchema#string

William H Shrank

http://www.w3.org/2001/XMLSchema#string

P2860

A strategy to reduce cardiovascular disease by more than 80%

Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis

Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey

Combination pharmacotherapy for cardiovascular disease

Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease

The underutilization of cardiac medications of proven benefit, 1990 to 2002

Adherence with statin therapy in elderly patients with and without acute coronary syndromes

Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis

A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone

P304

1261-1268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.107.735605

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Elliott M Antman

P577

2008-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18285564

http://www.w3.org/2001/XMLSchema#string

P921

P932

2722033

http://www.w3.org/2001/XMLSchema#string